MORRISVILLE,Funded in part by a recent investment, TEAMM
Pharmaceuticals has completed its initial growth phase, with the hiring and training of 50 professional sales representatives and support staff.

They will help market the Histex line of products that TEAMM acquired from Andrx Laboratories in July. The company also continues to promote Diabetic Tussin C. These products compete in a $2 billion plus cough, cold and allergy marketplace in the United States.

TEAMM says it will launch an additional product specific to the diabetes patient population, as well as a newly developed cough and cold line in December year. The company says its sales and marketing force will place primary emphasis on this newly developed line of products, in coordination with its development partner.

“We are very excited to have built the sales force to this critical point of our growth phase,” Martin G. Baum, president and chief executive officer of TEAMM, said in a statement. “Through acquisitions and the development of our new product line to be launched this winter, TEAMM will be positioned as the solutions based pharmaceutical company for cough, cold and allergy.”

After TEAMM landed $6.5 million from a group of investors led by Alabama-based Harbert Management in August, Baum told Local Tech Wire that the two-year-old company would use some of the funding to hire new workers.

TEAMM also says it will continue to expand to support the growth of its newly developed product lines. This focused promotional effort will allow for TEAMM to achieve positive earnings in 2002, it says.

TEAMM Pharmaceuticals: